Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03892421
What this trial is testing

Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma

Who this might be right for
Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma
La Raza Medical Center 22
Testing effectiveness (Phase 2)Study completedNCT00096096
What this trial is testing

Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+4 more
Fred Hutchinson Cancer Center
Very early researchEnded earlyNCT04034446
What this trial is testing

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Who this might be right for
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China 2
Early research (Phase 1)WithdrawnNCT05519527
What this trial is testing

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Who this might be right for
Refractory T Acute Lymphoblastic LeukemiaAcute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Large-scale testing (Phase 3)Study completedNCT03476239
What this trial is testing

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Acute Lymphoblastic Leukemia
Amgen 121
Testing effectiveness (Phase 2)UnknownNCT01354457
What this trial is testing

Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+

Who this might be right for
Acute Lymphoblastic Leukemia
Nantes University Hospital 21
Early research (Phase 1)Study completedNCT00005946
What this trial is testing

Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
University of Maryland, Baltimore
Early research (Phase 1)WithdrawnNCT05487495
What this trial is testing

Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

Who this might be right for
T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Beijing Boren Hospital
Testing effectiveness (Phase 2)Active Not RecruitingNCT02690545
What this trial is testing

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Who this might be right for
LymphomaLymphoma, Non-HodgkinImmune System Diseases+5 more
UNC Lineberger Comprehensive Cancer Center 38
Early research (Phase 1)Ended earlyNCT02082977
What this trial is testing

Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma

Who this might be right for
CancerNeoplasms
GlaxoSmithKline 41
Early research (Phase 1)Looking for participantsNCT06313957
What this trial is testing

LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed B-cell Non-Hodgkin LymphomaRefractory B-cell Non-Hodgkin Lymphoma
Peking University Cancer Hospital & Institute 42
Testing effectiveness (Phase 2)Study completedNCT00276003
What this trial is testing

INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.

Who this might be right for
Non-Hodgkin's LymphomaCancer
University of New Mexico 22
Testing effectiveness (Phase 2)Study completedNCT00787761
What this trial is testing

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Who this might be right for
Myeloproliferative DisordersKidney CancerLeukemia+4 more
Northside Hospital, Inc. 24
Testing effectiveness (Phase 2)Study completedNCT01492088
What this trial is testing

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory Hodgkin LymphomaRelapsed or Refractory Anaplastic Large-cell Lymphoma
Millennium Pharmaceuticals, Inc. 36
Early research (Phase 1)Ended earlyNCT00725062
What this trial is testing

Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant

Who this might be right for
Graft Versus Host DiseaseLeukemiaLymphoma+2 more
Masonic Cancer Center, University of Minnesota 3
Testing effectiveness (Phase 2)Study completedNCT03820596
What this trial is testing

Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL

Who this might be right for
Safety and Efficacy
Huiqiang Huang 40
Early research (Phase 1)Study completedNCT00004862
What this trial is testing

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Who this might be right for
Leukemia
National Cancer Institute (NCI) 24
Testing effectiveness (Phase 2)Looking for participantsNCT05643742
What this trial is testing

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Who this might be right for
B-cell LymphomaNon-Hodgkin LymphomaB-cell Malignancy+5 more
CRISPR Therapeutics AG 120
Early research (Phase 1)Ended earlyNCT02702141
What this trial is testing

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non-Hodgkin LymphomaDLBCLDiffuse Large B-cell Lymphoma+1 more
Seagen Inc. 44
Testing effectiveness (Phase 2)Study completedNCT04438005
What this trial is testing

ICP-022 in Patients With R/R DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd. 3
Next Page